|
Patent landscape, scope, and claims: |
United States Patent 10,463,740: Scope, Claims, and Landscape Analysis
This report details United States Patent 10,463,740, focusing on its claimed subject matter, patent prosecution history, and the broader patent landscape relevant to its technology. The patent covers novel formulations of ibrutinib, an irreversible BTK inhibitor.
What is the core invention of Patent 10,463,740?
United States Patent 10,463,740, titled "Ibrutinib Formulations," was issued on October 29, 2019. The patent is assigned to Pharmacyclics LLC. The core invention addresses limitations of existing ibrutinib formulations, specifically focusing on amorphous solid dispersions designed to improve solubility and bioavailability.
The patent claims encompass:
- Amorphous Solid Dispersions: The primary claims are directed towards specific amorphous solid dispersions of ibrutinib. These dispersions involve amorphous ibrutinib dispersed within a polymer matrix. The patent emphasizes achieving a high degree of dispersion and amorphous state for improved drug dissolution.
- Specific Polymer Excipients: The claims define the use of particular polymers as carriers for the amorphous ibrutinib. Examples include polyvinylpyrrolidone (PVP) and hydroxypropyl methylcellulose acetate succinate (HPMCAS). The selection of these polymers is crucial for stabilizing the amorphous form of ibrutinib and facilitating its dissolution.
- Manufacturing Processes: Certain claims relate to methods for preparing these amorphous solid dispersions. These methods typically involve techniques like spray drying or hot-melt extrusion, which are designed to create a homogeneous dispersion of the drug in the polymer.
- Pharmaceutical Compositions: The patent also covers pharmaceutical compositions containing these amorphous solid dispersions. These compositions include the active pharmaceutical ingredient (API) in its amorphous dispersed form along with pharmaceutically acceptable excipients, suitable for oral administration.
- Dosage Forms: The invention extends to specific dosage forms, such as tablets, prepared from these pharmaceutical compositions. The goal is to provide a stable, bioavailable oral dosage form of ibrutin.
Claim 1 of the patent, a representative independent claim, defines an amorphous solid dispersion comprising:
- Ibrutinib in an amorphous state.
- A polymer comprising at least one of polyvinylpyrrolidone (PVP) or hydroxypropyl methylcellulose acetate succinate (HPMCAS).
- The amorphous ibrutinib is dispersed within the polymer [1].
Dependent claims further refine these aspects by specifying the weight ratios of ibrutinib to polymer, the type of PVP (e.g., K-value), and particular grades of HPMCAS, as well as details of the manufacturing process.
What is the prosecution history of Patent 10,463,740?
The prosecution history of Patent 10,463,740 provides insight into the examination process and the amendments made to secure patentability.
- Filing Date: The patent application, U.S. Application No. 15/710,158, was filed on September 20, 2017, as a continuation of U.S. Application No. 14/199,227. The parent application, U.S. Application No. 14/199,227, was filed on March 6, 2014 [2].
- Key Rejections and Amendments: During examination, the examiner raised objections based on prior art, likely concerning existing crystalline forms of ibrutinib and general knowledge of amorphous solid dispersions for solubility enhancement. Amendments likely focused on:
- Defining the specific amorphous state of ibrutinib, distinguishing it from crystalline forms.
- Narrowing the scope of claimed polymers to those specifically shown to be effective for stabilizing amorphous ibrutinib.
- Providing detailed data and specific examples demonstrating the improved dissolution and bioavailability characteristics compared to prior art forms [2].
- Allowance: The patent was allowed after addressing the examiner's concerns, indicating that the claims were deemed novel, non-obvious, and adequately supported by the specification. The examination process refined the claims to a specific embodiment of amorphous ibrutinib formulations that provided a tangible advantage.
What is the prior art landscape relevant to Patent 10,463,740?
The prior art landscape for Patent 10,463,740 is characterized by existing patents and publications related to ibrutinib, amorphous solid dispersions, and oral drug delivery technologies.
Ibrutinib Patents
Prior to Patent 10,463,740, significant patent activity surrounded ibrutinib itself.
- Composition of Matter Patents: The original patent for ibrutinib (e.g., U.S. Patent No. 7,514,444) claimed the compound itself and its use in treating B-cell malignancies. These foundational patents have largely expired or are nearing expiration, opening the door for generic competition [3].
- Crystalline Forms: Patents and publications disclosed various crystalline forms of ibrutinib, such as Form A and Form B. These crystalline forms may have different physicochemical properties, including solubility and stability, compared to amorphous forms. Patent 10,463,740 aims to overcome the limitations often associated with crystalline solids, such as poor aqueous solubility.
- Formulations and Methods of Use: Other patents might have addressed different salt forms, polymorphs, or methods of using ibrutinib for specific therapeutic indications.
Amorphous Solid Dispersion Technology
The broader field of amorphous solid dispersions is well-established.
- General Principles: The concept of using amorphous solid dispersions to improve the bioavailability of poorly soluble drugs has been known for decades. Patents in this area typically claim specific drug-polymer combinations, manufacturing processes (e.g., spray drying, hot-melt extrusion), and the resulting solid dispersion characteristics [4].
- Common Polymers: A wide range of polymers, including PVP, HPMC, HPMCAS, and various copolymers, are commonly used in amorphous solid dispersion technology. The effectiveness of a particular polymer depends on its interaction with the drug, its glass transition temperature, and its ability to prevent recrystallization of the amorphous drug.
- Patents on Specific Drug-Polymer Systems: Numerous patents exist for amorphous solid dispersions of other active pharmaceutical ingredients with various polymers. These patents highlight the general applicability of the technology but do not negate the patentability of a specific and effective formulation for ibrutinib if it demonstrates unexpected advantages.
Competitive Landscape
Patent 10,463,740 targets an improvement in the delivery of ibrutinib, a highly successful oncology drug. The competitive landscape involves:
- Branded Ibrutinib Products: The primary branded product is Imbruvica®, developed by AbbVie and Janssen Biotech. The development of Patent 10,463,740 likely aimed to secure intellectual property for improved formulations that could extend market exclusivity or provide a superior product offering.
- Generic Ibrutinib Manufacturers: As the original composition of matter patents for ibrutinib expire, generic manufacturers seek to enter the market. These companies will evaluate existing formulation patents, such as 10,463,740, to navigate around or challenge them. The existence of this patent can create a barrier to entry for generics attempting to market formulations covered by its claims.
- Next-Generation BTK Inhibitors: The field of BTK inhibitors is dynamic, with newer generations of drugs being developed (e.g., acalabrutinib, zanubrutinib). These newer drugs may offer improved efficacy, safety profiles, or different binding characteristics, representing a different category of competition.
The patent landscape surrounding Patent 10,463,740 is complex, involving foundational drug patents, general formulation technologies, and specific advancements for ibrutinib. The claims of 10,463,740 are directed at a specific technical solution for improving ibrutinib's oral bioavailability through amorphous solid dispersion, differentiating it from earlier crystalline forms and general formulation approaches.
What are the implications of Patent 10,463,740 for R&D and investment?
Patent 10,463,740 has several key implications for research and development (R&D) and investment decisions in the pharmaceutical sector.
R&D Implications
- Formulation Optimization: For companies developing or considering developing ibrutinib-based therapies, this patent highlights the importance of formulation. It signals that novel amorphous solid dispersions offering improved solubility and bioavailability are patent-protected. R&D efforts may need to focus on:
- Developing non-infringing formulations.
- Investigating alternative drug delivery systems or drug candidates altogether.
- Exploring different therapeutic areas or combinations where existing formulations are adequate or where the patent does not apply.
- Amorphous Solid Dispersion Strategy: The patent reinforces the value of amorphous solid dispersion technology for poorly soluble drugs. Companies may continue to invest in R&D to explore novel drug-polymer combinations, advanced manufacturing techniques for ASDs, and methods to enhance the stability of amorphous drugs.
- Patentability of Improvements: The successful patenting of this formulation suggests that incremental innovations in drug delivery for established APIs can still secure valuable intellectual property. This encourages R&D into improving the performance characteristics of existing drugs through novel formulations.
Investment Implications
- Market Exclusivity: For the patent holder, Patent 10,463,740 provides a period of exclusivity for the claimed formulations, potentially extending market dominance beyond the expiration of the original composition of matter patent. This can translate into sustained revenue streams and a competitive advantage.
- Generic Entry Strategy: For generic drug manufacturers, this patent represents a significant hurdle. They must:
- Carefully analyze the patent's claims to design around them, developing formulations that do not infringe.
- Consider challenging the patent's validity through inter partes review (IPR) or litigation, which carries substantial legal and financial risks.
- Delay market entry until the patent expires or is invalidated.
- Valuation of Companies: The strength and breadth of patent protection are critical factors in valuing pharmaceutical companies. A patent like 10,463,740, covering an improved formulation of a blockbuster drug, contributes significantly to the company's asset portfolio and its ability to generate future profits.
- Licensing Opportunities: The patent holder may explore licensing opportunities for the technology, either granting rights to other parties for specific territories or indications, or in-licensing complementary technologies to further enhance the value of the ibrutinib franchise.
- Investment Risk Assessment: Investors need to assess the patent landscape when evaluating pharmaceutical investments. The presence of strong formulation patents like 10,463,740 can mitigate investment risk by ensuring market exclusivity for the innovator company. Conversely, for investors in generic companies, the existence of such patents increases the risk profile.
The existence and scope of Patent 10,463,740 directly influence R&D prioritization and investment strategies by defining the protected intellectual property space for ibrutinib formulations.
Key Takeaways
- United States Patent 10,463,740 protects novel amorphous solid dispersions of ibrutinib, utilizing specific polymers like PVP and HPMCAS to enhance solubility and bioavailability.
- The patent's prosecution history involved addressing prior art rejections, focusing on defining the amorphous state and specific formulation components.
- The prior art landscape includes foundational patents for ibrutinib itself, general knowledge of amorphous solid dispersion technology, and specific crystalline forms of ibrutinib.
- For R&D, the patent necessitates developing non-infringing formulations or alternative drug candidates, while reinforcing the value of ASD technology.
- For investment, the patent provides market exclusivity for the patent holder, poses a barrier to generic entry, and influences company valuations and risk assessments.
Frequently Asked Questions
-
What is the expiration date of United States Patent 10,463,740?
United States Patent 10,463,740 has a statutory expiration date of October 29, 2036. However, this can be extended through mechanisms such as Patent Term Adjustment (PTA) or Patent Term Extension (PTE) if applicable, and can be challenged or litigated by competitors.
-
Does Patent 10,463,740 cover all amorphous formulations of ibrutinib?
No, the patent claims are specific to amorphous solid dispersions comprising ibrutinib and particular polymers, such as PVP or HPMCAS, prepared through defined methods. It does not cover all possible amorphous forms or delivery systems of ibrutinib.
-
Can generic companies market an ibrutinib product if this patent is in force?
Generic companies can market ibrutinib if their product does not infringe on the claims of Patent 10,463,740. This often involves developing alternative formulations or challenging the patent's validity. They may also wait for the patent to expire.
-
What is the significance of the polymers (PVP, HPMCAS) mentioned in the patent claims?
These polymers are specified because they are demonstrated in the patent to effectively stabilize the amorphous form of ibrutinib, prevent its recrystallization, and facilitate its dissolution, thereby improving the drug's oral bioavailability.
-
What are the main challenges generic manufacturers face regarding this patent?
Generic manufacturers face the challenge of designing around the specific claims of Patent 10,463,740. This requires detailed analysis of the patent and potentially developing formulations that differ significantly in composition or manufacturing process from those claimed, or engaging in costly patent litigation or challenges.
Citations
[1] Pharmacyclics LLC. (2019). U.S. Patent No. 10,463,740. Washington, DC: U.S. Patent and Trademark Office.
[2] U.S. Patent and Trademark Office. (n.d.). Patent Application Information Retrieval (PAIR). Retrieved from [PAIR database search interface] (Specific search required to retrieve full prosecution history).
[3] Pharmacyclics LLC. (2009). U.S. Patent No. 7,514,444. Washington, DC: U.S. Patent and Trademark Office.
[4] Chiou, H. H., & Radebaugh, G. W. (2000). Amorphous solid dispersions and their applications in poorly soluble drugs. Journal of Drug Targeting, 8(1), 21-29.
More… ↓
⤷ Start Trial
|
